Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Cariprazine 1.5 mg Hard Capsules and Reagila in Healthy Adults Under Fasting Conditions
NCT07691190Phase 1Completed
- Sponsor
- Humanis
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cariprazine in schizophrenia (2 arms), sponsored by Humanis. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve from Zero to 72 Hours and Maximum Measured Plasma Concentration at 72 hours. Started Mar 2026; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07691190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691190.